J. Formento

发表

Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture

P. Giraud, F. Penault-Llorca, J. Thariat, 2012, Clinical Cancer Research.

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer.

N. Magné, G. Poissonnet, O. Dassonville, 2005, Oral oncology.

An EGFR Pathway-Oriented Pharmacogenetic Study in MetastaticColorectal Cancer Patients Receiving Panitumumab and Irinotecan

C. Tournigand, P. Laurent-Puig, H. Blons, 2016 .

Imaging , Diagnosis , Prognosis EpidermalGrowthFactorReceptorProteinDetection inHead and Neck Cancer Patients : A Many-Faceted Picture

P. Giraud, J. Thariat, O. Dassonville, 2012 .

EGFR in colorectal cancer: more than a simple receptor.

C. Létoublon, G. Milano, P. Lasser, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

G. Milano, L. Mineur, M. Etienne-Grimaldi, 2010, British journal of clinical pharmacology.

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

Amine Sadok, H. Kovacic, J. Seitz, 2009, British journal of pharmacology.

RESEARCH PAPER Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

Amine Sadok, H. Kovacic, J. Seitz, 2009 .

EGFR expression in colon cancer: a break in the clouds.

F. Penault-Llorca, G. Milano, M. Etienne-Grimaldi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

J. Douillard, G. Milano, M. Etienne-Grimaldi, 2012, British journal of clinical pharmacology.

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

P. Laurent-Puig, C. Létoublon, G. Milano, 2008, Clinical Cancer Research.

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

N. Magné, P. Laurent-Puig, C. Létoublon, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Steroid receptors in human osteoblast-like cells.

M. Namer, G. Milano, J. Fischel, 1990, European journal of cancer.

Epidermal growth factor receptor in upper aerodigestive tract cancer

A. Ramaioli, O. Dassonville, F. Demard, 1994 .

Monitoring NF-κB Transactivation Potential Via Real-Time PCR Quantification of IκB-α Gene Expression

V. Imbert, J. Peyron, V. Bottero, 2012, Molecular Diagnosis.

Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation.

G. Milano, M. Etienne-Grimaldi, J. Fischel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinically applicable assay for tumoral thymidylate synthase combining reverse transcriptase-PCR and high-performance liquid chromatography.

G. Milano, P. Formento, M. Francoual, 1998, European journal of cancer.

Candidate mechanisms for capecitabine-related hand-foot syndrome.

G. Milano, P. Hofman, M. Etienne-Grimaldi, 2008, British journal of clinical pharmacology.

Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.

G. Poissonnet, O. Dassonville, G. Pagès, 2009, Pharmacogenomics.

Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells

F. Lévi, G. Milano, F. Delaunay, 2005, Journal of Molecular Medicine.

Thyroid activity during hepatocarcinogenesis by N-2-fluorenylacetamide

M. Lafaurie, J. Formento, C. Aussel, 2004, Journal of Cancer Research and Clinical Oncology.

Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas

F Demard, G Milano, O. Dassonville, 1991, Head & neck.

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

J. Gaudart, G. Milano, L. Ouafik, 2011, BMC Cancer.

Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up.

A. Ramaioli, M. Namer, G. Milano, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.

N. Magné, G. Milano, M. Etienne-Grimaldi, 2007, British journal of clinical pharmacology.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

N. Magné, C. Létoublon, G. Milano, 2004, Pharmacogenetics.

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.

G Milano, C. Létoublon, G. Milano, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

K-RasMutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive FluoropyrimidineTherapy

P. Laurent-Puig, C. Létoublon, D. Pezet, 2008 .

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

Improvement of quality control for steroid receptor measurements: Analysis of distributions in more than 40000 primary breast cancers

F. Spyratos, S. Romain, H. Magdelenat, 2005, Breast Cancer Research and Treatment.

Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences.

G. Milano, S. Romain, M. Francoual, 1994, European journal of cancer.

Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer

M. Namer, G. Milano, J. Fischel, 2005, Breast Cancer Research and Treatment.

P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up.

A. Ramaioli, M. Namer, G. Milano, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Application of an original RT-PCR–ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients

M. Namer, G. Milano, F. Ettore, 1999, British Journal of Cancer.

The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.

N. Magné, G. Poissonnet, O. Dassonville, 2001, European journal of cancer.

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

M. Namer, G. Milano, R. Largillier, 2006, Clinical Cancer Research.

Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome.

G Milano, P Grellier, P. Paquis, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression.

V. Imbert, J. Peyron, V. Bottero, 2003, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

N. Magné, A. Dubreuil, G. Milano, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.

F Demard, G Milano, A. Ramaioli, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 genetic polymorphism and pharmacodynamics of trastuzumab-based treatment in breast cancer patients

M. Campone, G. Milano, R. Largillier, 2005 .

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.

G. Milano, M. Etienne-Grimaldi, M. Francoual, 2007, Pharmacogenomics.

Prospective study of dihydropyrimidine dehydrogenase (DPD) activity and DPYD IVS14+1G>A mutation in patients developing FU-related toxicities: An updated analysis based on a ten-year recruitment across multiple French institutions

N. Magné, G. Milano, M. Etienne-Grimaldi, 2005 .

HPLC micromethod for simultaneous measurement of estradiol, progesterone, androgen and glucocorticoid receptor levels. Application to breast cancer biopsies.

M. Namer, B. Krebs, G. Milano, 1987, European journal of cancer & clinical oncology.

Oestrogen and progesterone receptor status in bone biopsy specimens from patients with breast cancer.

M. Namer, G. Milano, M. Francoual, 1991, European journal of cancer.

Simultaneous micro measurement of steroid receptors in breast cancer.

M. Namer, B. Krebs, G. Milano, 1983, British Journal of Cancer.

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

N. Magné, F. Lévi, G. Milano, 2003, European journal of cancer.

Taxotere–5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells

Joseph Ciccolini, G Milano, G. Milano, 2005, Anti-cancer drugs.

Dihydropyrimidine dehydrogenase circadian rhythms for both enzyme activity and gene expression from mouse liver

F. Lévi, G. Milano, E. Filipski, 2000 .

Hand-foot syndrome (HFS) in patients receiving capecitabine: A pharmacological explanation.

G. Milano, P. Hofman, M. Etienne-Grimaldi, 2006, Journal of Clinical Oncology.

Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance

A. Ramaioli, G. Pagès, J. Formento, 2006, British Journal of Cancer.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

P. Laurent-Puig, J. Formento, G. Milano, 2004, British Journal of Cancer.

Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.

C. Létoublon, J. Formento, G. Milano, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

N. Magné, G. Poissonnet, O. Dassonville, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen metabolism: pharmacokinetic and in vitro study.

M. Namer, J. Formento, G. Milano, 1989, British Journal of Cancer.

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

N. Magné, A. Dubreuil, J. Formento, 2003, British Journal of Cancer.